
Biologics Contract Development Market by Source (Mammalian, Microbial), Type (Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins), Disease Indication, Phase, Service Type, End-User - Global Forecast 2024-2030
Description
Biologics Contract Development Market by Source (Mammalian, Microbial), Type (Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins), Disease Indication, Phase, Service Type, End-User - Global Forecast 2024-2030
The Biologics Contract Development Market size was estimated at USD 6.54 billion in 2023 and expected to reach USD 7.30 billion in 2024, at a CAGR 11.79% to reach USD 14.28 billion by 2030.
Global Biologics Contract Development Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Biologics Contract Development Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biologics Contract Development Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Biologics Contract Development Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JRS PHARMA GmbH & Co. KG, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..
Market Segmentation & Coverage
This research report categorizes the Biologics Contract Development Market to forecast the revenues and analyze trends in each of the following sub-markets:
Source
Mammalian
Microbial
Type
Molecular Therapy
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Disease Indication
Cardiovascular Disorders
Hematological Disorders
Immunological Disorders
Oncology
Phase
Phase I
Phase II
Phase III
Preclinical
Service Type
Cell Line Development
Mammalian
Microbial
Process Development
Downstream
Impurity, Isolation, & Identification
Pharmaceutical Analysis
Physicochemical Characterization
Upstream
Mammalian
Microbial
End-User
Biopharmaceutical Companies
Research Laboratories
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Biologics Contract Development Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biologics Contract Development Market?
3. What are the technology trends and regulatory frameworks in the Biologics Contract Development Market?
4. What is the market share of the leading vendors in the Biologics Contract Development Market?
5. Which modes and strategic moves are suitable for entering the Biologics Contract Development Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
188 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Biologics Contract Development Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing demand for vaccine and biosimilar production
- 5.1.1.2. Government initiatives encouraging biologics activities
- 5.1.1.3. Improved operational efficiency and cost saving with biologics CDO
- 5.1.2. Restraints
- 5.1.2.1. Communication issues between end-user and CDO
- 5.1.3. Opportunities
- 5.1.3.1. Technological advancements in biologics development systems
- 5.1.3.2. Investments in new biologics contract development services expansion
- 5.1.4. Challenges
- 5.1.4.1. Concerns associated with breach of intellectual property
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Biologics Contract Development Market, by Source
- 6.1. Introduction
- 6.2. Mammalian
- 6.3. Microbial
- 7. Biologics Contract Development Market, by Type
- 7.1. Introduction
- 7.2. Molecular Therapy
- 7.3. Monoclonal Antibodies
- 7.4. Recombinant Proteins
- 7.5. Vaccines
- 8. Biologics Contract Development Market, by Disease Indication
- 8.1. Introduction
- 8.2. Cardiovascular Disorders
- 8.3. Hematological Disorders
- 8.4. Immunological Disorders
- 8.5. Oncology
- 9. Biologics Contract Development Market, by Phase
- 9.1. Introduction
- 9.2. Phase I
- 9.3. Phase II
- 9.4. Phase III
- 9.5. Preclinical
- 10. Biologics Contract Development Market, by Service Type
- 10.1. Introduction
- 10.2. Cell Line Development
- 10.3.1. Mammalian
- 10.3.2. Microbial
- 10.3. Process Development
- 10.4.1. Downstream
- 10.4.2.1. Impurity, Isolation, & Identification
- 10.4.2.2. Pharmaceutical Analysis
- 10.4.2.3. Physicochemical Characterization
- 10.4.2. Upstream
- 10.4.3.1. Mammalian
- 10.4.3.2. Microbial
- 11. Biologics Contract Development Market, by End-User
- 11.1. Introduction
- 11.2. Biopharmaceutical Companies
- 11.3. Research Laboratories
- 12. Americas Biologics Contract Development Market
- 12.1. Introduction
- 12.2. Argentina
- 12.3. Brazil
- 12.4. Canada
- 12.5. Mexico
- 12.6. United States
- 13. Asia-Pacific Biologics Contract Development Market
- 13.1. Introduction
- 13.2. Australia
- 13.3. China
- 13.4. India
- 13.5. Indonesia
- 13.6. Japan
- 13.7. Malaysia
- 13.8. Philippines
- 13.9. Singapore
- 13.10. South Korea
- 13.11. Taiwan
- 13.12. Thailand
- 13.13. Vietnam
- 14. Europe, Middle East & Africa Biologics Contract Development Market
- 14.1. Introduction
- 14.2. Denmark
- 14.3. Egypt
- 14.4. Finland
- 14.5. France
- 14.6. Germany
- 14.7. Israel
- 14.8. Italy
- 14.9. Netherlands
- 14.10. Nigeria
- 14.11. Norway
- 14.12. Poland
- 14.13. Qatar
- 14.14. Russia
- 14.15. Saudi Arabia
- 14.16. South Africa
- 14.17. Spain
- 14.18. Sweden
- 14.19. Switzerland
- 14.20. Turkey
- 14.21. United Arab Emirates
- 14.22. United Kingdom
- 15. Competitive Landscape
- 15.1. FPNV Positioning Matrix
- 15.2. Market Share Analysis, By Key Player
- 15.3. Competitive Scenario Analysis, By Key Player
- 16. Competitive Portfolio
- 16.1. Key Company Profiles
- 16.1.1. AbbVie, Inc.
- 16.1.2. Abzena Ltd.
- 16.1.3. Aenova Holding GmbH
- 16.1.4. AGC Biologics GmbH
- 16.1.5. Avid Bioservices, Inc.
- 16.1.6. Binex Co. Limited
- 16.1.7. Boehringer Ingelheim International GmbH
- 16.1.8. Cambrex Corporation
- 16.1.9. Catalent, Inc.
- 16.1.10. Emergent BioSolutions, Inc.
- 16.1.11. Fujifilm Holdings Corporation
- 16.1.12. Icon PLC
- 16.1.13. JRS PHARMA GmbH & Co. KG
- 16.1.14. JSR Life Sciences, LLC
- 16.1.15. Lonza Group AG
- 16.1.16. Parexel International Corporation
- 16.1.17. ProBioGen AG
- 16.1.18. Recipharm AB
- 16.1.19. Rentschler Biopharma SE
- 16.1.20. Samsung Biologics
- 16.1.21. Takeda Pharmaceutical Company Limited
- 16.1.22. Thermo Fisher Scientific, Inc.
- 16.1.23. Toyobo Co., Ltd.
- 16.1.24. WuXi Biologics Inc.
- 16.2. Key Product Portfolio
- 17. Appendix
- 17.1. Discussion Guide
- 17.2. License & Pricing
- FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET RESEARCH PROCESS
- FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. BIOLOGICS CONTRACT DEVELOPMENT MARKET DYNAMICS
- FIGURE 7. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
- FIGURE 8. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 10. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
- FIGURE 12. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
- FIGURE 14. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
- FIGURE 16. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 18. BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 22. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 24. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 27. BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 28. BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.